Clinical Immunology · STAT1 Gain-of-Function Syndrome

Treatment Strategies: Standard Care, JAK Inhibitors, and HSCT

At a Glance

Treatment for STAT1-GOF syndrome usually begins with infection prevention, especially antifungal therapy, with antibiotics or IVIG for selected patients. JAK inhibitors may calm abnormal immune signaling, while a stem cell transplant is reserved for severe cases and carries major risks.

Managing STAT1 Gain-of-Function (STAT1-GOF) Syndrome requires a multi-layered approach. Because the condition affects both how you fight infections and how your immune system treats your own body, treatment ranges from daily preventive medications to targeted therapies that address the underlying signaling ^[1]^[2].

Standard Infection Management

The first priority for most patients is controlling the cycle of infections. This is often managed through “prophylaxis”—taking medication to prevent an illness before it starts.

Antifungals: Because yeast infections (Chronic Mucocutaneous Candidiasis) are so persistent, specialists often recommend continuous, daily antifungal medication or intermittent treatment based on clinical severity, culture/speciation, and prior resistance ^[3]. Missed doses or suboptimal dosing is associated with azole resistance, where the fungus learns to ignore the medication ^[3]^[2].
Therapeutic Drug Monitoring (TDM): To ensure the medicine is safe and effective, doctors use TDM—a specialized blood test to measure the exact amount of antifungal in your system. This is used for selected azoles like voriconazole or posaconazole to ensure the dose is “just right” ^[4]^[5]^[6].
Antibiotics and IVIG: For those with frequent lung or sinus infections, antibiotics may be used. Some patients also receive Intravenous Immunoglobulin (IVIG), which is generally considered for documented antibody dysfunction or recurrent serious bacterial infections, even if the patient’s own antibody levels appear normal on standard tests ^[7]^[8]. Normal immunoglobulin levels alone are not a reason for IVIG.

Targeted Therapy: JAK Inhibitors

In recent years, doctors have begun using JAK inhibitors (such as ruxolitinib or baricitinib) to treat the dysregulated signaling of STAT1-GOF. These medications are “off-label,” meaning they were originally approved for other conditions but are used here because they modulate downstream signaling to specifically “dial down” the overactive STAT1 signal ^[9]^[10].

How They Work: They block the JAK proteins that tell STAT1 to turn on. By quieting this signal, they can help the body’s anti-fungal defenses recover and reduce autoimmune attacks ^[1]^[11]. They do not correct the gene.
Clinical Success: In observational research groups, about 87% of STAT1-GOF patients saw partial or complete improvement in their symptoms while taking these medications ^[9]^[10]. However, improvement is not guaranteed or necessarily durable.
Monitoring Risks: These are powerful drugs that require close supervision. Doctors monitor for cytopenias (low blood cell counts), serious or opportunistic infection, lipid abnormalities, weight gain, and “viral reactivation,” where old viruses (like cold sores or CMV) might try to return while the immune system is being calmed ^[9]^[10]^[12]. Pretreatment tuberculosis and hepatitis screening is required.
The “Rebound” Effect: If a JAK inhibitor is stopped suddenly, symptoms can return quickly or even worsen. Any taper or discontinuation must be directed by your prescriber ^[13]^[14].

Curative Intent: Bone Marrow Transplant (HSCT)

Hematopoietic Stem Cell Transplantation (HSCT)—also called a bone marrow transplant—is potentially curative for the hematopoietic immune defect of STAT1-GOF. It involves replacing your immune system with a healthy one from a donor ^[15]^[16].

When It’s Considered: HSCT is usually reserved for severe cases, such as life-threatening infections, progressive lung disease, or severe autoimmunity that doesn’t respond to other treatments ^[15]^[17].
Survival and Risks: This is a high-risk procedure. A study of transplants between 2010 and 2023 showed an overall survival rate of 72.2% ^[15]. Risks include Graft-versus-Host Disease (GvHD), graft failure, organ toxicity, infertility, infection, and treatment-related mortality ^[15]^[18]. It may not reverse established organ damage.
Preparing for Success: Research suggests that using a JAK inhibitor to quiet inflammation before transplant is an emerging, center-specific strategy rather than an established protocol ^[15]^[19].

Choosing a Path

Your care plan will evolve over time. While most begin with standard infection management, the decision to move to targeted drugs or a transplant is a personal one made in close partnership with a specialized immunology team ^[20]^[21].

Common questions in this guide

What treatments are usually used first for STAT1-GOF syndrome?

Initial care focuses on preventing and treating infections. This may include continuous or intermittent antifungal medicine, antibiotics for recurrent lung or sinus infections, and IVIG for selected people with documented antibody problems or recurrent serious bacterial infections; normal immunoglobulin levels alone do not justify IVIG.

Why might my antifungal level be checked?

Therapeutic drug monitoring measures the amount of certain antifungal medicines, such as voriconazole or posaconazole, in the blood. It helps clinicians adjust the dose for safety and effectiveness and may help avoid underdosing that contributes to resistance.

Can JAK inhibitors help people with STAT1-GOF syndrome?

Ruxolitinib and baricitinib are off-label medicines that reduce overactive signaling connected to STAT1. They may improve fungal defense and autoimmune problems in some patients, but response is not guaranteed, may not last, and these medicines do not repair the underlying gene.

What monitoring is needed during JAK inhibitor treatment?

Clinicians typically monitor blood counts, infections, blood fats, weight, and signs that viruses such as herpes viruses or cytomegalovirus have become active again. Screening for tuberculosis and hepatitis is required before treatment, and the medicine should not be stopped suddenly because symptoms can rebound.

When is a stem cell transplant considered for STAT1-GOF syndrome?

HSCT, also called a bone marrow transplant, may be considered when infections are life-threatening, lung disease is progressing, or severe autoimmunity does not respond to other treatments. It can potentially correct the blood-forming immune defect, but it may not reverse organ damage.

How risky is HSCT for STAT1-GOF syndrome?

HSCT can cause graft-versus-host disease, graft failure, organ toxicity, infertility, serious infection, and treatment-related death. In a study of transplants performed from 2010 through 2023, overall survival was 72.2%, but the risks and likely benefit depend on the individual and transplant center.

Get notified when new evidence is published on STAT1-related autoimmune enteropathy and endocrinopathy-susceptibility to chronic infections syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Key takeaways

Antifungal treatment is selected according to infection severity, cultures, and prior resistance, with drug-level testing used for some azole medicines.
Ruxolitinib and baricitinib are off-label JAK inhibitors that may improve fungal defense and autoimmunity but do not correct the STAT1 gene.
JAK inhibitors require monitoring for low blood counts, serious infections, viral reactivation, lipid changes, and other adverse effects, and they should not be stopped suddenly.
HSCT may be considered for life-threatening infections, progressive lung disease, or severe autoimmunity that does not respond to other treatments.
HSCT can potentially correct the blood-forming immune defect but carries risks including graft-versus-host disease, graft failure, organ toxicity, infertility, infection, and treatment-related death.

References (21)

1
Human STAT1 Gain-of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I Interferonopathy.
Okada S, Asano T, Moriya K, et al.
Journal of clinical immunology 2020; (40(8)):1065-1081 doi:10.1007/s10875-020-00847-x.
PMID: 32852681
2
Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype.
Toubiana J, Okada S, Hiller J, et al.
Blood 2016; (127(25)):3154-64 doi:10.1182/blood-2015-11-679902.
PMID: 27114460
3
Clinical heterogeneity of dominant chronic mucocutaneous candidiasis disease: presenting as treatment-resistant candidiasis and chronic lung disease.
Dotta L, Scomodon O, Padoan R, et al.
Clinical immunology (Orlando, Fla.) 2016; (164()):1-9.
PMID: 26732859
4
Evaluating a voriconazole dose modification guideline to optimize dosing in patients with hematologic malignancies.
Perreault S, McManus D, Anderson A, et al.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2019; (25(6)):1305-1311 doi:10.1177/1078155218786028.
PMID: 29996736
5
Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021.
Chau MM, Daveson K, Alffenaar JC, et al.
Internal medicine journal 2021; (51 Suppl 7()):37-66 doi:10.1111/imj.15587.
PMID: 34937141
6
Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium.
McCreary EK, Davis MR, Narayanan N, et al.
Pharmacotherapy 2023; (43(10)):1043-1050 doi:10.1002/phar.2850.
PMID: 37459118
7
Qualitative Immunoglobulin Deficiency Causes Bacterial Infections in Patients with STAT1 Gain-of-Function Mutations.
Chen R, Mu H, Chen X, et al.
Journal of clinical immunology 2024; (44(5)):124 doi:10.1007/s10875-024-01720-x.
PMID: 38758476
8
Clinical Relevance of Gain- and Loss-of-Function Germline Mutations in STAT1: A Systematic Review.
Zhang W, Chen X, Gao G, et al.
Frontiers in immunology 2021; (12()):654406 doi:10.3389/fimmu.2021.654406.
PMID: 33777053
9
JAK inhibitor treatment for inborn errors of JAK/STAT signaling: An ESID/EBMT-IEWP retrospective study.
Fischer M, Olbrich P, Hadjadj J, et al.
The Journal of allergy and clinical immunology 2024; (153(1)):275-286.e18 doi:10.1016/j.jaci.2023.10.018.
PMID: 37935260
10
Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain of Function (GOF) Mutations-10 Children and Review of the Literature.
Deyà-Martínez A, Rivière JG, Roxo-Junior P, et al.
Journal of clinical immunology 2022; (42(5)):1071-1082 doi:10.1007/s10875-022-01257-x.
PMID: 35486339
11
Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation.
Weinacht KG, Charbonnier LM, Alroqi F, et al.
The Journal of allergy and clinical immunology 2017; (139(5)):1629-1640.e2 doi:10.1016/j.jaci.2016.11.022.
PMID: 28139313
12
Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation.
Moriya K, Suzuki T, Uchida N, et al.
International journal of hematology 2020; (112(2)):258-262 doi:10.1007/s12185-020-02860-7.
PMID: 32180118
13
Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation.
Bloomfield M, Kanderová V, Paračková Z, et al.
Journal of clinical immunology 2018; (38(5)):589-601 doi:10.1007/s10875-018-0519-6.
PMID: 29934865
14
Ruxolitinib Improves Immune-Dysregulation Features but not Epigenetic Abnormality in a Patient with STAT1 GOF.
Koh JY, Kim DR, Son S, et al.
Journal of clinical immunology 2024; (44(4)):84 doi:10.1007/s10875-024-01687-9.
PMID: 38578320
15
Improved outcome of HSCT in STAT1 gain-of-function disease following JAK inhibition bridging.
Buddingh EP, Slatter M, Becerra JCA, et al.
Journal of human immunity 2025; (1(3)) doi:10.70962/jhi.20250027.
PMID: 41142635
16
Hematopoietic Stem Cell Transplantation in Patients with Heterozygous STAT1 Gain-of-Function Mutation.
Kiykim A, Charbonnier LM, Akcay A, et al.
Journal of clinical immunology 2019; (39(1)):37-44 doi:10.1007/s10875-018-0575-y.
PMID: 30543054
17
The T385M STAT1 gain-of-function mutation confers the most severe disease outcomes.
Torrance R, McKenna AJ, King C, et al.
Frontiers in immunology 2025; (16()):1717692 doi:10.3389/fimmu.2025.1717692.
PMID: 41394881
18
Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations.
Leiding JW, Okada S, Hagin D, et al.
The Journal of allergy and clinical immunology 2018; (141(2)):704-717.e5 doi:10.1016/j.jaci.2017.03.049.
PMID: 28601685
19
Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation.
Kayaoglu B, Kasap N, Yilmaz NS, et al.
Journal of clinical immunology 2021; (41(4)):769-779 doi:10.1007/s10875-020-00943-y.
PMID: 33475942
20
Case report: Myocarditis in congenital STAT1 gain-of function.
Staels F, Roosens W, Giovannozzi S, et al.
Frontiers in immunology 2023; (14()):1095595 doi:10.3389/fimmu.2023.1095595.
PMID: 37020552
21
Janus Kinase Inhibitors in Treatment of Primary Immune Regulatory Disorders.
Alsaati NF, Satter LF
The journal of allergy and clinical immunology. In practice 2026; (14(7)):1491-1503 doi:10.1016/j.jaip.2026.05.019.
PMID: 42409456

This page describes treatment options for STAT1-GOF syndrome for informational purposes only and does not constitute medical advice. A specialized immunology team should tailor infection prevention, JAK inhibitor monitoring, and HSCT decisions to the patient’s condition.